Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study-Reference-Cited by-同舟云学术

Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study

Published:2020 Issue:9 Volume:67 Page:957-962
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Aoki Kazutaka¹²,Kamiyama Hiroshi³,Takihata Masahiro⁴,Taguri Masataka⁵,Shibata Eriko²,Shinoda Kazuaki⁶,Yoshii Taishi⁷,Nakajima Shigeru⁸,Terauchi Yasuo²

Affiliation:

1. Internal Medicine, Kanagawa Dental University, Yokosuka, Japan

2. Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan

3. Kamiooka Diabetes Metabolism Naika Clinic, Yokohama, Japan

4. Miura Central Clinic, Miura, Japan

5. Department of Data Science, Yokohama City University School of Data Science, Yokohama, Japan

6. Konandai Naika Clinic, Yokohama, Japan

7. Oppama Yoshii Naika Clinic, Yokosuka, Japan

8. Nakajima Naika Clinic, Yokosuka, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/67/9/67_EJ19-0464/_pdf

Reference22 articles.

1. 1 Herman GA, Bergman A, Stevens C, Kotey P, Yi B, et al. (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91: 4612–4619.

2. 2 Gallwitz B (2011) Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs 71: 1675–1688.

3. 3 Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) multicentre randomised placebo-controlled trial. Lancet 364: 685–696.

4. 4 Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005–2016.

5. 5 Tajima N, Kurata H, Nakaya N, Mizuno K, Ohashi Y, et al. (2008) Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis 199: 455–462.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group;Diabetes Therapy;2024-07-11

2. Effect of Liraglutide combined with Jinlida granules on glycolipid metabolism and islet function of type 2 diabetes mellitus;Cellular and Molecular Biology;2024-02-29

3. The Possible Effect of the Long-Term Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Hba1c and Lipid Profile in Type 2 Diabetes Mellitus: A Retrospective Study in KAUH, Jeddah, Saudi Arabia;Diseases;2023-03-14

4. Exenatide prevents statin-related LDL receptor increase and improves insulin secretion in pancreatic beta cells (1.1E7) in a protein kinase A-dependent manner;Journal of Applied Biomedicine;2022-12-20

5. A new era in gut hormone-based pharmacotherapy for people with obesity;Proceedings of the Nutrition Society;2022-09